Johnson & Johnson JNJ Innovative Medicine — Goodwill, related to acquisitions

Other segment segments

MEDTECH

$0—

Similar metrics at other companies

AVAHMedical Solutions — Goodwill Acquired

$0—

SUNBSpecialty — Goodwill related to acquisitions

$16.25M+6,400%

VREXMedical — Goodwill

$173.5M—

ADPTImmune Medicine Business — Goodwill

$22.6M0.0%

AMRXAffordable Medicines — Goodwill

$158.02M-2.3%

RMDGoodwill on acquisition

$18.94M—

Other financials

Income statement

See full

Revenue$24.1B+9.9%

Gross profit$16.0B+9.8%

Operating income$6.3B+2.3%

Net income$5.2B-52.4%

EPS (diluted)$2.14-52.9%

Balance sheet

See full

Cash & equivalents$21.7B-43.6%

Total debt$55.0B+5.2%

Total equity$81.2B+3.9%

Total assets$200.89B+3.7%

Cash flow

See full

Operating cash flow$2.5B-39.8%

CapEx$1.0B+31.9%

Free cash flow$1.5B-56.6%

Valuation

See full

Market cap$623.71B+66.9%

Enterprise value$657.01B+61.9%

P/E29.6×+13.2×

P/S6.5×+2.3×

Profitability

See full

Gross margin67.8%-0.5pp

Operating margin26.4%+2.8pp

Net margin21.8%-2.6pp

FCF margin18.5%-4.3pp

Returns & leverage

See full

Return on equity26.4%-3.0pp

Debt / equity0.7×0.0×

Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:GoodwillAcquiredDuringPeriod.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's innovative medicine — goodwill, related to acquisitions.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Johnson & Johnson's innovative medicine — goodwill, related to acquisitions?: Johnson & Johnson (JNJ) reported innovative medicine — goodwill, related to acquisitions of $0 in Q1 2026.
What does innovative medicine — goodwill, related to acquisitions mean?: Captures the specific portion of goodwill added to the Innovative Medicine segment balance sheet resulting from inorganic growth activities. This metric tracks the premium paid for acquired pharmaceutical companies or product pipelines. It is a key indicator of the company's strategy to expand its therapeutic footprint through external investment.